Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies

British Journal of Surgery

Volumn 102, Issue 12, 2015, Pages 1448-1458

  Levolger, S ^a   Van Vugt, J L A ^a   De Bruin, R W F ^a   IJzermans, J N M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL SURGERY; BILIARY TRACT NEOPLASMS; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; GASTROINTESTINAL NEOPLASMS; HEALTH; HUMAN; LIVER NEOPLASMS; MORBIDITY; PANCREATIC NEOPLASMS; SARCOPENIA; TRENDS;

BILIARY TRACT NEOPLASMS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; GASTROINTESTINAL NEOPLASMS; GLOBAL HEALTH; HUMANS; LIVER NEOPLASMS; MORBIDITY; PANCREATIC NEOPLASMS; SARCOPENIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84944161372     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9893     Document Type: Review

References (58)

1. Kehlet H, Wilmore DW,. Multimodal strategies to improve surgical outcome. Am J Surg 2002; 183: 630-641.
2. Varadhan KK, Neal KR, Dejong CH, Fearon KC, Ljungqvist O, Lobo DN,. The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: a meta-analysis of randomized controlled trials. Clin Nutr 2010; 29: 434-440.
3. Spanjersberg WR, Reurings J, Keus F, van Laarhoven CJ,. Fast track surgery versus conventional recovery strategies for colorectal surgery. Cochrane Database Syst Rev 2011; (2)CD007635.
4. Kehlet H., Fast-track colorectal surgery. Lancet 2008; 371: 791-793.
5. Zhuang CL, Ye XZ, Zhang XD, Chen BC, Yu Z,. Enhanced recovery after surgery programs versus traditional care for colorectal surgery: a meta-analysis of randomized controlled trials. Dis Colon Rectum 2013; 56: 667-678.
6. Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ,; Participants in the VA National Surgical Quality Improvement Program. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg 2005; 242: 326-341.
7. Kirchhoff P, Clavien PA, Hahnloser D,. Complications in colorectal surgery: risk factors and preventive strategies. Patient Saf Surg 2010; 4: 5.
8. Pedersen T., Complications and death following anaesthesia. A prospective study with special reference to the influence of patient-, anaesthesia-, and surgery-related risk factors. Dan Med Bull 1994; 41: 319-931.
9. Tan KY, Kawamura YJ, Tokomitsu A, Tang T,. Assessment for frailty is useful for predicting morbidity in elderly patients undergoing colorectal cancer resection whose comorbidities are already optimized. Am J Surg 2012; 204: 139-143.
10. Saxton A, Velanovich V,. Preoperative frailty and quality of life as predictors of postoperative complications. Ann Surg 2011; 253: 1223-1229.
11. DePinho RA,. The age of cancer. Nature 2000; 408: 248-254.
12. Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 2015; 26: 463-476.
13. Hamaker ME, Prins MC, Schiphorst AH, van Tuyl SA, Pronk A, van den Bos F,. Long-term changes in physical capacity after colorectal cancer treatment. J Geriatr Oncol 2015; 6: 153-164.
14. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146-M156.
15. Milte R, Crotty M,. Musculoskeletal health, frailty and functional decline. Best Pract Res Clin Rheumatol 2014; 28: 395-410.
16. Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, et al. Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int 2012; 23: 1839-1848.
17. Roubenoff R., Sarcopenia: a major modifiable cause of frailty in the elderly. J Nutr Health Aging 2000; 4: 140-142.
18. Marzetti E, Leeuwenburgh C,. Skeletal muscle apoptosis, sarcopenia and frailty at old age. Exp Gerontol 2006; 41: 1234-1238.
19. Cherin P, Voronska E, Fraoucene N, de Jaeger C,. Prevalence of sarcopenia among healthy ambulatory subjects: the sarcopenia begins from 45 years. Aging Clin Exp Res 2014; 26: 137-146.
20. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423.
21. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-163.
22. Janssen I, Heymsfield SB, Ross R,. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50: 889-896.
23. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9: 629-635.
24. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-495.
25. Evans WJ,. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr 2010; 91: 1123S-1127S.
26. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793-799.
27. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME,. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008; 12: 1193-1201.
28. Antoun S, Baracos VE, Birdsell L, Escudier B, , Sawyer MB,. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21: 1594-1598.
29. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15: 2920-2926.
30. Fearon KC,. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008; 44: 1124-1132.
31. Tisdale MJ,. Mechanisms of cancer cachexia. Physiol Rev 2009; 89: 381-410.
32. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005; 8: 421-432.
33. Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ,. The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 2007; 57: 225-241.
34. Prado CM, Birdsell LA, Baracos VE,. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009; 3: 269-275.
35. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.
36. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp [accessed 20 May 2015].
37. Awad S, Tan BH, Cui H, Bhalla A, Fearon KC, Parsons CL, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 2012; 31: 74-77.
38. Yip C, Goh V, Davies A, Gossage J, Mitchell-Hay R, Hynes O, et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol 2014; 24: 998-1005.
39. Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg 2015; 261: 1173-1193.
40. Itoh S, Shirabe K, Matsumoto Y, Yoshiya S, Muto J, Harimoto N, et al. Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. Ann Surg Oncol 2014; 21: 3063-3068.
41. Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 2013; 100: 1523-1530.
42. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE,. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 2012; 107: 931-936.
43. Reisinger KW, van Vugt JLA, Tegels JJ, Snijders C, Hulsewé KW, Hoofwijk AG, et al,. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery Ann Surg 2015; 261: 345-352.
44. Van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, IJzermans JN,. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 2012; 99: 550-557.
45. Peng PD, Van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) 2011; 13: 439-446.
46. Sheetz KH, Zhao L, Holcombe SA, Wang SC, Reddy RM, Lin J, et al. Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer. Dis Esophagus 2013; 26: 716-722.
47. Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg 2012; 16: 1478-1486.
48. Sabel MS, Terjimanian M, Conlon AS, Griffith KA, Morris AM, Mulholland MW, et al. Analytic morphometric assessment of patients undergoing colectomy for colon cancer. J Surg Oncol 2013; 108: 169-175.
49. Jung HW, Kim JW, Kim JY, Kim SW, Yang HK, Lee JW, et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Supportive Care Cancer 2015; 23: 687-694.
50. Hasselager R, Gogenur I,. Core muscle size assessed by perioperative abdominal CT scan is related to mortality, postoperative complications, and hospitalization after major abdominal surgery: a systematic review. Langenbecks Arch Surg 2014; 399: 287-295.
51. Shen W, Punyanitya M, Wang Z, Gallagher D, , St-Onge MP, , Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 2004; 97: 2333-2338.
52. Lang PO, Michel JP, Zekry D,. Frailty syndrome: a transitional state in a dynamic process. Gerontology 2009; 55: 539-549.
53. Fearon KC, Glass DJ, Guttridge DC,. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012; 16: 153-166.
54. Argiles JM, Busquets S, Stemmler B, Lõpez-Soriano FJ,. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014; 14: 754-762.
55. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142: 531-543.
56. Jameson GS, Hoff DD, Weiss GJ, Donald R, Smith DA, Becerra C, et al. Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. J Clin Oncol 2012; 30 (Suppl): Abstract 2516.
57. Dingemans AM, de Vos-Geelen J, Langen R, Schols AM,. Phase II drugs that are currently in development for the treatment of cachexia. Expert Opin Investig Drugs 2014; 23: 1655-1669.
58. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539-1547.